In the clinic, Huangtu Decoction is applied to treat acute upper gastrointestinal bleeding, acute coronary syndrome compounded by acute upper gastrointestinal bleeding, bleeding arising from excessive antiplatelet and anticoagulant drugs, instances of unexplained positive fecal occult blood tests, bleeding gastrointestinal tumors, thrombocytopenia, and other acute, critical diseases. https://www.selleck.co.jp/products/gefitinib-hydrochloride.html Key to the hemostasis properties of Huangtu Decoction is the calibrated dosage of Cooking Stove Earthkey, Rehmanniae Radix, and Asini Corii Colla.
Shenqi Pills, initially mentioned in ZHANG Zhong-jing's “Essentials from the Golden Cabinet” (Jin Kui Yao Lue) during the Han dynasty, promote kidney Qi and Yang warmth and revitalization, and are primarily indicated for situations of kidney Qi and Yang insufficiency. From a modern medical perspective, kidney Qi is intricately linked to various bodily functions, such as heart function, kidney function, immune function, and beyond. Kidney deficiency, abnormal fluid imbalances, and abnormal urination, specifically including oliguria, polyuria, and dysuria, are the clinical signs of Shenqi Pills' efficacy. acute infection In the realm of clinical practice, Shenqi Pills find application in treating heart failure, kidney failure, cardiorenal syndrome, and resistance to diuretics, encompassing also endocrine, urological, orthopedic, and other persistent degenerative ailments. For those with a weak constitution and requiring immediate care, Shenqi Pills are an appropriate and effective solution. Examining the contextual meanings of classic texts through the integration of Traditional Chinese and Western medicine, specifically using 'pathogenesis integrated with pathology and drug properties integrated with pharmacology,' holds great value and significance.
The makeup of human illnesses, body types, and patterns of drug use have experienced remarkable changes, posing novel challenges to the safety of traditional Chinese medicine (TCM). Instances of liver and kidney injury caused by non-toxic Traditional Chinese Medicine (TCM) have led to a questioning of long-held assumptions surrounding its safety, undermining public confidence in the continued development of TCM and prompting a re-evaluation of existing understanding. In the current globalized environment, correctly comprehending the nuances of TCM safety and resolving the difficulties in evaluating and mitigating risks are crucial tasks for practitioners of Traditional Chinese Medicine. To ensure the safety of Traditional Chinese Medicine, this paper emphasizes the importance of an objective and dialectical analysis of its current situation and associated challenges, while also promoting the adoption of contemporary standards of use. This paper, furthermore, introduces a new conception and methodology in the field of TCM safety. It includes an innovative understanding, two types of evaluation methods, a tri-element injury hypothesis, four-quadrant risk decision-making processes, and a five-grade safety evidence system. The aim is to provide new theories, strategies, methods, and successful case studies for addressing safety issues in TCM.
The leaves of Vernonia amygdalina Delile, a plant of the Asteraceae family (more commonly known as 'bitter leaf'), have been used for a long time in West tropical Africa both for food and medicinal purposes, due to their abundance of biological activities. Southeast Asia and the Fujian and Guangdong provinces of China have recently seen their introduction. Nonetheless, the properties of the plant in traditional Chinese medicine (TCM) remain largely unknown, hindering its integration with other Chinese medicinal herbs. From PubMed, Web of Science, CNKI, Wanfang Data, and VIP, this study selected 473 articles focusing on V. amygdalina leaves to explore their chemical composition, pharmacological properties, and clinical studies. RNAi-based biofungicide V. amygdalina foliage demonstrates a spectrum of pharmacological properties, including antimicrobial, hypoglycemic, antihypertensive, lipid-lowering, anti-tumor, anti-inflammatory, antioxidant, and other related effects. TCM principles indicate that the leaves possess a cold nature, combined with a bitter and sweet flavor. This affects the spleen, liver, stomach, and large intestine, demonstrating heat-clearing, dampness-drying, fire-purging, toxin-removing, insect-killing, and malaria-preventing effects. These substances can be employed in the treatment of dampness-heat diarrhea, interior heat, diabetes, malaria, insect accumulation, and eczema. A decoction of 5-10 grams of dried leaves daily, and appropriate amounts of fresh crushed leaves applied externally are advised. V. amygdalina leaves find little medicinal use in China, as they do not possess the desired properties essential to Traditional Chinese Medicine. The characterization of the medicinal properties in the leaves encourages the incorporation of new exotic medicinal herbs and the augmentation of Traditional Chinese Medicine's resources, thereby enabling enhanced clinical usage and research and development in the realm of Chinese herbal medicine.
With the purpose of activating blood, resolving stasis, and moving Qi to relieve pain, Jingtong Granules is a frequently used therapy for cervical radiculopathy in China. The prescription's efficacy in alleviating neck, shoulder, and upper limb pain, stiffness, and the prickling numbness or pain associated with this condition has been demonstrably proven through prolonged clinical application and supporting evidence. In spite of its promise, the clinical implementation of Jingtong Granules is not universally agreed upon. In view of this, the compilation of this expert consensus involved the invitation of clinical first-line experts and methodology specialists from the entirety of the country. Clinicians are anticipated to utilize Jingtong Granules in a consistent and justifiable manner, thanks to this expert consensus, which aims to enhance clinical outcomes, minimize medication-related risks, and ultimately benefit patients. Jingtong Granules' indications, clinical manifestations, therapeutic benefits, and potential side effects were outlined based on the consensus of expert clinical experience and standard development procedures. Clinical practitioners in traditional Chinese medicine and Western medicine were interviewed in person, and clinical applications were examined. From these data, clinical challenges were extracted, and a shared consensus developed through the nominal group technique, forming the definitive list of clinical problems. For the clinical problems, a search for supporting evidence was executed, and the discovered evidence was critically evaluated, in the third instance. In rating the quality of evidence, the GRADE system was applied. A summary of 5 recommendations and 3 consensus items was achieved through the application of the nominal group method, as part of the fourth phase. Expert meetings and letter reviews were employed to solicit opinions and peer reviews pertaining to the consensus content. Clinicians in hospitals and primary healthcare facilities can find a valuable resource in the final consensus; it summarizes the evidence on the clinical indications, effectiveness, and safety of Jingtong Granules.
This research sought to determine the effectiveness and safety profile of Biling Weitong Granules in addressing stomach ache disorder. An investigation of Biling Weitong Granules' efficacy in treating digestive ailments, particularly stomach ache, was conducted by reviewing randomized controlled trials (RCTs) sourced from Chinese and English electronic databases and trial registries, spanning from database inception to June 10, 2022. Literature screening and data extraction were performed by two investigators, adhering to the established screening criteria. In order to determine the risk of bias present in the included studies, the Cochrane risk-of-bias tool (version 20) was employed. RevMan 54 and R 42.2 were used for the analyses, which involved calculating summary estimates using fixed or random effects models. The primary outcome measures were the visual analogue scale (VAS) scores, along with scores indicative of stomach ache disorder symptoms. Secondary outcome indicators included the clinical recovery rate, the Helicobacter pylori (Hp) eradication rate, and adverse reactions or events. A review of 2,902 cases across 27 randomized controlled trials was undertaken. A meta-analysis study assessed Biling Weitong Granules against conventional Western medicine treatments or placebo, revealing improvements in various factors: VAS scores (SMD = -190, 95% CI [-218, -161], P < 0.00001), stomach ache symptom scores (SMD = -126, 95% CI [-171, -82], P < 0.00001), clinical recovery rates (RR = 185, 95% CI [166, 208], P < 0.00001), and eradication rate of H. pylori (RR = 128, 95% CI [120, 137], P < 0.00001). The evaluation of Biling Weitong Granules' safety revealed adverse events such as nausea, vomiting, rash, diarrhea, loss of appetite, and a bitter mouth sensation; no serious adverse effects were observed. Egger's test, upon analysis, showed no statistically significant results, indicating the absence of publication bias. Biling Weitong Granules for digestive diseases, specifically stomach ache, demonstrated effectiveness in improving VAS and stomach ache symptom scores, contributing to enhanced clinical recovery and Hp eradication rates. These improvements occurred with good safety and without any serious adverse reactions. Although this was the case, the initial research demonstrated a low quality, hampered by specific constraints. To bolster the reliability of clinical evidence supporting the application of this medicine, future studies must utilize unified and standardized detection methods and evaluation criteria for outcome indicators, carefully consider the rigor of study design and implementation, and prominently feature the medicine's clinical safety.
This study delved into the possible association between traditional Chinese medicine (TCM) and a lower rate of readmission in patients with rheumatoid arthritis and hypoproteinemia (RA-H). Between 2014 and 2021, the information system database at the First Affiliated Hospital of Anhui University of Chinese Medicine was scrutinized for a retrospective cohort study of 2,437 rheumatoid arthritis patients. Analysis revealed that 476 of these patients exhibited hypoproteinemia.